BioAlliance Pharma presents preclinical and phase I clinical results with its AMEP® biotherapy for metastatic melanoma

At the "Electrochemotherapy 1st International Users' Meeting"
(Bologna, Italy, November 19-20, 2010)

Paris, November 23, 2010 – BioAlliance Pharma SA (Euronext Paris – BIO), a company dedicated to the supportive care and treatment of cancer patients, presented preclinical and promising preliminary phase I clinical results with its AMEP® biotherapy at the "Electrochemotherapy 1st International Users' Meeting" (Bologna, Italy, November 19-20, 2010).

The AMEP® biotherapy is indicated for metastatic and invasive melanoma, an advanced skin cancer refractory to most treatments. Its original mechanism of action targets specific receptors (integrins), particularly expressed by melanoma cells, both involved in tumor growth and tumor angiogenesis.

Preclinical efficacy and safety results supporting ongoing phase I clinical trial were presented. This latter trial evaluates safety and efficacy of intratumoral electrotransfer of AMEP® biotherapy in patients suffering from advanced or metastatic melanoma. It is being conducted in 3 specialized centers: in Denmark at the Copenhagen University Herlev Hospital, in France at the Gustave Roussy Institute of Villejuif and in Slovenia at the Institute of Oncology of Ljubljana.

Preliminary phase I clinical trial results showed a satisfactory safety and a well accepted electrotransfer technology in the first patients treated with the AMEP® biotherapy

"These preliminary results confirm the interest of the anti-invasive AMEP® biotherapy in BioAlliance's clinical programme portfolio; it represents a potential disrupting technology project", explains Pierre Attali, COO of BioAlliance Pharma, in charge of Strategy and Medical Affairs. "This program is co-financed by OSEO's Strategic Industrial Innovation Programme to the "Cancer Anti-invasive Program" (CAP) consortium, associating the academic research, industrials and melanoma clinicians. This high quality consortium extends the scope of the program to a "companion" markers research, helpful in the follow-up of these severe patients", adds Dominique Costantini, CEO.

About « Electrochemotherapy 1st International Users' Meeting » (Bologna, November 19-20, 2010)
First international meeting dedicated to the electrotransfer technology and organized by IGEA, a company which develops devices and technologies in the field of clinical biophysics. The electrotransfer technology enables chemical or biological substances to be transferred to target cells thanks to an effective, safe, simple, and repeatable delivery of electric pulses. For the first time, European clinicians met to exchange their practices and innovations brought by the electrotransfer technology. Used for several years in chemotherapy for cutaneous and subcutaneous metastatic lesions, notably in skin, breast and head & neck cancers, this technology is now used for the transfer of biological active substances, such as plasmids.

About BioAlliance Pharma
Dedicated to cancer and supportive care – cancer related pathologies, chemotherapy and radiotherapy-induced complications and opportunistic infections in immunocompromised patients – BioAlliance conceives and develops innovative products, especially in the hospital setting and for orphan or rare diseases.
Created in 1997 and introduced to the Euronext Paris market in 2005, BioAlliance Pharma's ambition is to become a leading player in these fields by coupling innovation to patient needs. The company's teams have the key competencies required to identify, develop and register drugs in Europe and the USA; the products' commercialization rights are licensed to international commercial partners invested in the hospital setting. In areas where medical needs are insufficiently met, its targeted approaches help overcome drug resistance and improve patient health & quality of life.

BioAlliance Pharma has developed an advanced product portfolio:
Loramyc®/Oravig® (oropharyngeal candidiasis in immunocompromised patients): Registered in 26 European countries, in Korea and in the United States
Setofilm® (prevention and treatment of -chemotherapy, radiotherapy and post operative- induced nausea and vomiting in adults and children): Registered in 16 European countries
Acyclovir Lauriad® (labialis herpes): Positive phase III final results; registration status
Fentanyl Lauriad® (chronic cancer pain): Positive preliminary Phase I results
AMEP® (invasive melanoma): Phase I
Clonidine Lauriad® (mucositis): Phase II
Doxorubicin Transdrug® (liver cancer): Phase II
For more information, visit the BioAlliance Pharma web site at www.bioalliancepharma.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the 2009 Reference Document filed with the AMF on June 29, 2010, which is available on the AMF website (http://www.amf-france.org) or on BioAlliance Pharma SA's website (http://www.bioalliancepharma.com).

BioAlliance Pharma SA
Dominique Costantini, CEO
Tel.: +33 1 45 58 76 01
dominique.costantini@bioalliancepharma.com
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00
nicolas.fellmann@bioalliancepharma.com

ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59
caroline@alizerp.com